Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
London pre-open: Stocks to fall as attention turns to Budget
(Sharecast News) - London stocks were set to drop at the open on Wednesday ahead of the Autumn Budget. The FTSE 100 was called to open around 30 points lower, with Chancellor Rachel Reeves due to deliver her first Budget after Prime Minister's Questions.
Steve Clayton, head of equity funds at Hargreaves Lansdown, said: "Retail investors are bracing themselves ahead of what is widely expected to be one of the most significant Budget days of recent years. Rachel Reeves has had only a few months to determine the magnitude of the UK's fiscal challenges, let alone work out the measures needed to correct the course and enable the new Government to start to execute its plans.
"Changes to pensions, capital gains tax, inheritance tax and employers NI have all been mooted in the press.
"The headline numbers look likely to be big, with estimates of the sums needing to be raised having risen to as much as £40bn."
In corporate news, GSK reported a 2% increase in constant exchange rate sales in its third-quarter results, to £8bn, with strong specialty medicines growth offsetting a 15% decline in vaccine sales, affected by shifts in US vaccination priorities.
The FTSE 100 pharmaceuticals giant said that while total operating profit fell 86% due to a £1.8bn Zantac settlement charge, core operating profit and earnings per share each rose 5%, driven by specialty medicines and cost management.
It reaffirmed its 2024 guidance, expecting turnover growth of 7% to 9% and mid-range core profit growth, with a third quarter dividend of 15p and a projected full-year dividend of 60p.
Next lifted its guidance for both the crucial fourth quarter and the full year, after the recent cold snap caused sales to surge.
Updating on trading, the blue chip retailer said full price sales surged 7.6% in the 13 weeks to 26 October, well ahead of the 5% uplift it had forecast.
Next attributed the better-than-expected performance to the arrival of colder weather this year, which compared favourably to last year's unusually warm September and early October.
As a result, Next lifted guidance for fourth-quarter full price sales, to 3.5%, and full-year profits and sales.
It now expects 2024/25 sales to come in at £5.02bn, compared to its previous forecast for £4.98bn, with pre-tax profits topping £1bn, at £1.005bn. That would be an 9.5% increase on the previous year.
Total group sales - which include markdowns and subsidiaries - are forecast to be £6.27bn, up 7.4% year-on-year.
Prior to Wednesday's update, Next had expected full-year pre-tax profits to come in at £995m on sales of £4.98bn.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.